AstraZeneca (AZN) Stock Rating Reaffirmed by Citigroup
AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by equities research analysts at Citigroup in a research report issued on Wednesday.
Other equities research analysts have also issued research reports about the stock. Goldman Sachs Group set a GBX 3,900 ($52.49) target price on shares of AstraZeneca and gave the stock a “sell” rating in a report on Friday, August 18th. Investec upped their target price on shares of AstraZeneca from GBX 4,900 ($65.95) to GBX 5,500 ($74.02) and gave the stock a “buy” rating in a report on Monday, November 6th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca in a report on Monday, September 11th. Barclays set a GBX 6,300 ($84.79) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, September 13th. Finally, Berenberg Bank set a GBX 5,800 ($78.06) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, September 19th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 5,169 ($69.57).
Shares of AstraZeneca (LON AZN) opened at GBX 4,935 ($66.42) on Wednesday. AstraZeneca has a fifty-two week low of GBX 4,134.50 ($55.65) and a fifty-two week high of GBX 5,520 ($74.29).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.